These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 30643947)

  • 1. Routinely staging gastric cancer with
    Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
    Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
    Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
    Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of CT attenuation and F-18 fluorodeoxyglucose uptake of visceral adipose tissue for predicting survival in gastric cancer patients after curative surgical resection.
    Lee JW; Son MW; Chung IK; Cho YS; Lee MS; Lee SM
    Gastric Cancer; 2020 Mar; 23(2):273-284. PubMed ID: 31485803
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
    Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of baseline
    Foley KG; Coomer W; Coles B; Bradley KM
    Br J Radiol; 2022 Oct; 95(1139):20220437. PubMed ID: 36129138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
    Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
    Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer.
    Oh HH; Lee SE; Choi IS; Choi WJ; Yoon DS; Min HS; Ra YM; Moon JI; Kang YH
    J Surg Oncol; 2011 Oct; 104(5):530-3. PubMed ID: 21618250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-tumor metabolic heterogeneity of gastric cancer on
    Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
    Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
    Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
    Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
    Jakobsen JK; Frahm Nielsen T; Ipsen P; Albrecht-Beste E; Cardoso Costa J; Alslev L; Predbjørn Krarup K; Grønkaer Toft B; Høyer S; Bouchelouche K; Bjerggaard Jensen J
    BJU Int; 2021 Feb; 127(2):254-262. PubMed ID: 33448605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
    Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
    Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
    Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
    J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT with
    Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of
    de Jongh C; van der Meulen MP; Gertsen EC; Brenkman HJF; van Sandick JW; van Berge Henegouwen MI; Gisbertz SS; Luyer MDP; Nieuwenhuijzen GAP; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; de Steur WO; Hartgrink HH; Stoot JHMB; Hulsewe KWE; Spillenaar Bilgen EJ; van Det MJ; Kouwenhoven EA; Daams F; van der Peet DL; van Grieken NCT; Heisterkamp J; van Etten B; van den Berg JW; Pierie JP; Eker HH; Thijssen AY; Belt EJT; van Duijvendijk P; Wassenaar E; Wevers KP; Hol L; Wessels FJ; Haj Mohammad N; Frederix GWJ; van Hillegersberg R; Siersema PD; Vegt E; Ruurda JP;
    Ann Surg Oncol; 2024 Jun; 31(6):4005-4017. PubMed ID: 38526832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.